Merck and Kelun-Biotech revealed Phase 3 breast cancer data for the lead antibody-drug conjugate in their potentially $12 billion partnership. In a Phase 3 trial for locally recurrent or ...

Senate Finance Committee Chair Ron Wyden (D-OR) is urging HHS to take a stronger stance on healthcare companies' cybersecurity practices as the healthcare system is still piecing together what ...

A New Jersey federal judge on Monday tossed cases brought by Johnson & Johnson and Bristol Myers Squibb against the Inflation Reduction Act, another victory for the law while Medicare ...

In early August, Teva hit a bump in producing the popular ADHD drug Adderall, as the company faced a backorder of the drug in 20 mg and 30 mg ...

Bristol Myers Squibb said its KRAS cancer drug Krazati met the primary endpoint in a Phase 3 confirmatory trial in patients with non-small cell lung cancer, according to new data ...

Madrigal Pharmaceuticals is “making great progress” on the rollout of its NASH drug Rezdiffra, executives said less than a month post-launch. Rezdiffra was approved in March as ...

'We strong­ly dis­sent': Women biotech ex­ecs pen let­ter to col­leagues and politi­cians in Roe v. Wade af­ter­math ...

Up until recently, Alban de La Sablière was Sanofi’s chief dealmaker, reporting directly to CEO Paul Hudson without officially being a C-suite executive. That's now changed with de La Sabli ...

Ada­gio raised $750M+ for an an­ti­body against fu­ture vari­ants. It failed against Omi­cron ...

The next generation of Operation Warp Speed is coming soon, and this time it's going to take aim at rare diseases, Peter Marks, the director of the FDA's Center for ...

Un­der the gun with Aduhelm floun­der­ing, Bio­gen sells its stake in biosim­i­lars busi­ness for $2.3B ...

CVS Health is shutting down the clinical trials business that it launched just two years ago, part of an effort to focus on its core business. CVS confirmed the move ...